Causal relationship between gut microbiota, lipids, and neuropsychiatric disorders: A Mendelian randomization mediation study DOI
Nan Zhang, Xiaoyu Dong

Journal of Affective Disorders, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH DOI Open Access
Frank Tacke, Tobias Puengel, Rohit Loomba

и другие.

Journal of Hepatology, Год журнала: 2023, Номер 79(2), С. 552 - 566

Опубликована: Апрель 14, 2023

Язык: Английский

Процитировано

158

Gut liver brain axis in diseases: the implications for therapeutic interventions DOI Creative Commons

Mengyao Yan,

Shuli Man,

Benyue Sun

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Дек. 6, 2023

Gut-liver-brain axis is a three-way highway of information interaction system among the gastrointestinal tract, liver, and nervous systems. In past few decades, breakthrough progress has been made in gut liver brain axis, mainly through understanding its formation mechanism increasing treatment strategies. this review, we discuss various complex networks including barrier permeability, hormones, microbial metabolites, vagus nerve, neurotransmitters, immunity, toxic β-amyloid (Aβ) metabolism, epigenetic regulation gut-liver-brain axis. Some therapies containing antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), polyphenols, low FODMAP diet nanotechnology application regulate Besides, some special treatments targeting gut-liver include farnesoid X receptor (FXR) agonists, takeda G protein-coupled 5 (TGR5) glucagon-like peptide-1 (GLP-1) antagonists fibroblast growth factor 19 (FGF19) analogs. Targeting gut-brain embraces cognitive behavioral therapy (CBT), antidepressants tryptophan metabolism-related therapies. liver-brain contains Aβ future, better interactions will promote development novel preventative strategies discovery precise therapeutic targets multiple diseases.

Язык: Английский

Процитировано

86

Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases DOI Creative Commons
Susana Rodrigues, Van der Merwe, Aleksander Krag

и другие.

Seminars in Immunology, Год журнала: 2024, Номер 71, С. 101859 - 101859

Опубликована: Янв. 21, 2024

Язык: Английский

Процитировано

19

Why Do So Many Nonalcoholic Steatohepatitis Trials Fail? DOI Open Access
Vlad Ratziu, Scott L. Friedman

Gastroenterology, Год журнала: 2020, Номер 165(1), С. 5 - 10

Опубликована: Май 18, 2020

Язык: Английский

Процитировано

71

Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions DOI Creative Commons

Jayashi Rajapakse,

Saroj Khatiwada,

Anna Camille Akon

и другие.

Gut Microbes, Год журнала: 2023, Номер 15(2)

Опубликована: Авг. 24, 2023

Hepatocellular carcinoma (HCC) has been linked to the gut microbiota, with recent studies revealing potential of gut-generated responses influence several arms immune relevant HCC formation. The pro- or anti-tumor effects specific bacterial strains microbiota-related metabolites, such as bile acids and short-chain fatty acids, have highlighted in many human animal studies. critical role microbiota development spurred interest modulating through dietary interventions, probiotics, fecal transplantation a strategy improve liver cancer outcomes. Encouragingly, preclinical clinical demonstrated that modulation can ameliorate function, reduce inflammation, inhibit tumor growth, underscoring this approach As research continues unravel complex dynamic mechanisms underlying gut-liver axis, safe effective interventions target pathway for prevention treatment appears be on horizon, heralding significant advance our ongoing efforts combat devastating disease.

Язык: Английский

Процитировано

35

Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies DOI Creative Commons

M.J.M. de Koning,

Hilde Herrema, Max Nieuwdorp

и другие.

Gut Microbes, Год журнала: 2023, Номер 15(1)

Опубликована: Июнь 26, 2023

Humans possess abundant amounts of microorganisms, including bacteria, fungi, viruses, and archaea, in their gut. Patients with nonalcoholic fatty liver disease (NAFLD) exhibit alterations gut microbiome an impaired barrier function. Preclinical studies emphasize the significance pathogenesis NAFLD. In this overview, we explore how adjusting could serve as innovative therapeutic strategy for We provide a summary current information on untargeted techniques such probiotics fecal microbiota transplantation, well targeted microbiome-focused therapies engineered prebiotics, postbiotics, phages treatment

Язык: Английский

Процитировано

31

Health and Disease: Akkermansia muciniphila , the Shining Star of the Gut Flora DOI Creative Commons
Chen Xue,

Ganglei Li,

Xinyu Gu

и другие.

Research, Год журнала: 2023, Номер 6

Опубликована: Янв. 1, 2023

(

Процитировано

24

Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation DOI Creative Commons
Bozhong Shi, Haoyu Li, Xiaomin He

и другие.

Gut Microbes, Год журнала: 2024, Номер 16(1)

Опубликована: Фев. 27, 2024

The gut microbiome is known as the tenth system of human body that plays a vital role in intersection between health and disease. considerable inter-individual variability microbiota poses both challenges great prospects promoting precision medicine cardiovascular diseases (CVDs). In this review, based on development, evolution, influencing factors full life circle, we summarized recent advances characteristic alteration CVDs throughout different stages, depicted their pathological links mechanism, well highlight achievements targeting prevention, diagnosis treatment. Personalized strategies could be tailored according to characteristics including microbiota-blood metabolites combined prediction diagnosis, dietary interventions, lifestyle improvements, probiotic or prebiotic supplements. However, fulfill promise lifelong health, more mechanism studies should progress from correlation causality decipher novel mechanisms linking specific microbes CVDs. It also promising use burgeoning artificial intelligence machine learning target for developing screening new therapeutic interventions.

Язык: Английский

Процитировано

10

Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023) DOI Creative Commons
Xiaofei Zhu, Ziyuan Zhou,

Xiaxia Pan

и другие.

Frontiers in Microbiology, Год журнала: 2024, Номер 15

Опубликована: Март 14, 2024

The gut-liver axis has emerged as a focal point in chronic liver disorders, prompting more research into the role of gut microbiota cirrhosis. In individuals with cirrhosis, changes structure and function are closely tied to clinical prognosis. However, there is scarcity bibliometric evaluations conducted this particular field.

Язык: Английский

Процитировано

9

Mucoadhesive probiotic-based oral microcarriers with prolonged intestinal retention for inflammatory bowel disease therapy DOI
Kairuo Wang, Qian Chen,

Li Ding

и другие.

Nano Today, Год журнала: 2023, Номер 50, С. 101876 - 101876

Опубликована: Май 24, 2023

Язык: Английский

Процитировано

22